Two years ago, the Recovery trial transformed COVID treatments around the world with a landmark finding that may have saved a million lives in just nine months
In our first weekly update on COVID vaccines, we consider how roll-out plans are being tweaked and when it’s likely we’ll start to see vaccines having an impact.
There is now a third vaccine that prevents COVID-19 infections. It isn’t quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.
Experts from across The Conversation look at how COVID-19 vaccines will work, how they’re being tested and manufactured, and what challenges there will be to rolling them out.
The phase 3 trials of the University of Oxford/AstraZeneca vaccine have been paused because one participant became unwell. But we don’t know for sure if the illness was a reaction to the vaccine.
The Australian government is working with two major pharmaceutical companies to facilitate the local production and supply of two different COVID-19 vaccines – if they’re proven to be effective.
The vaccine hasn’t completed phase 3 trials, so we can’t be sure it will be safe and effective for all. The Australian government’s deal is contingent on these trials being successful.